Exchange
SSE STAR Market
Every company in the roster listed on SSE STAR Market.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
13 of 13 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Sichuan Baili Pharmaceutical688506 · SSE STAR Market | 9 assets: 3 Ph 3, 4 Ph 2, 2 Ph 1 | BL-B01D1Phase 3 · Non-Small Cell Lung Cancer | Nov 2026BL-B01D1 · Phase 3 |
 BeBetter Med688759 · SSE STAR Market | 4 assets: 2 Ph 3, 2 Ph 2 | BEBT-908Phase 3 · Multiple MyelomaWeak signal | Jun 2027BEBT-109 · Phase 2 |
 Bio-Thera Solutions688177 · SSE STAR Market | 3 assets: 3 approved | Approved assets only | None on record |
 Allist Pharmaceuticals688578 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 1 | AlflutinibPhase 3 · Non-Small Cell Lung Cancer | Dec 2026AST2303 ABK3376 · Phase 1 |
 Dizal Pharmaceuticals688192 · SSE STAR Market | 2 assets: 1 approved, 1 Ph 2 | DZD6008Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026Sunvozertinib · Phase 2 |
 Frontier Biotechnologies688221 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 2 | AlbuvirtidePhase 3 · HIVPartial signal | None on record |
 Suzhou Zelgen Biopharmaceuticals688266 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 2 | jaktinibPhase 3 · Atopic DermatitisPartial signal | Apr 2027ZG005 · Phase 1/2 |
 Asieris Pharmaceuticals688176 · SSE STAR Market | 1 asset: 1 Ph 1 | APL-1401Phase 1 · Ulcerative ColitisPartial signal | None on record |
 Genrix Bio688443 · SSE STAR Market | 1 asset: 1 Ph 3 | GR1803Phase 3 · Multiple MyelomaWeak signal | 12 May 2027GR1803 · Phase 2 |
 InventisBio688382 · SSE STAR Market | 1 asset: 1 Ph 3 | D-2570Phase 3 · Ulcerative ColitisPartial signal | 31 Oct 2026D-2570 · Phase 1 |
 Mabwell Bioscience688062 · SSE STAR Market | 1 asset: 1 Ph 2 | 9MW1911Phase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | Dec 20279MW1911 · Phase 2 |
 Sichuan Huiyu Pharmaceutical Co., Ltd688553 · SSE STAR Market | 1 asset: 1 Ph 2 | HYP-6589Phase 1/2 · Non-Small Cell Lung Cancer | 10 Apr 2028HYP-6589 · Phase 1/2 |
 Sunshine Guojian Pharmaceutical688336 · SSE STAR Market | 1 asset: 1 Ph 2 | SSGJ-627Phase 2 · Ulcerative Colitis | 28 Feb 2029SSGJ-627 · Phase 2 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).